{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:45:09Z","timestamp":1770439509577,"version":"3.49.0"},"reference-count":61,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.3892\/or.2013.2882","type":"journal-article","created":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T14:33:36Z","timestamp":1385649216000},"page":"771-780","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells"],"prefix":"10.3892","volume":"31","author":[{"given":"YEN TA","family":"HUANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHUAN CHU","family":"CHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TZU CHUN","family":"LIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TED H.","family":"CHIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PEI CHUN","family":"LAI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,11,28]]},"reference":[{"key":"key20180107222721_b1-or-31-02-0771","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1464-410X.2008.07962.x","article-title":"Bladder cancer, pathological classification and staging","volume":"102","author":"Tavora","year":"2008","journal-title":"BJU Int"},{"key":"key20180107222721_b2-or-31-02-0771","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00345-007-0168-5","article-title":"Epidemiology of urinary bladder cancer: from tumor development to patient's death","volume":"25","author":"Murta-Nascimento","year":"2007","journal-title":"World J Urol"},{"key":"key20180107222721_b3-or-31-02-0771","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.urology.2004.04.088","article-title":"Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy","volume":"64","author":"George","year":"2004","journal-title":"Urology"},{"key":"key20180107222721_b4-or-31-02-0771","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20180107222721_b5-or-31-02-0771","first-page":"31","article-title":"Gemcitabine in bladder cancer","volume":"27","author":"Sternberg","year":"2000","journal-title":"Semin Oncol"},{"key":"key20180107222721_b6-or-31-02-0771","article-title":"A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer","author":"Chaudhary","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"key20180107222721_b7-or-31-02-0771","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.eururo.2011.08.072","article-title":"Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01)","volume":"60","author":"Culine","year":"2011","journal-title":"Eur Urol"},{"key":"key20180107222721_b8-or-31-02-0771","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1464-410X.2008.08098.x","article-title":"Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin","volume":"103","author":"Muramaki","year":"2009","journal-title":"BJU Int"},{"key":"key20180107222721_b9-or-31-02-0771","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00345-007-0219-y","article-title":"Survivin: a promising biomarker for detection and prognosis of bladder cancer","volume":"26","author":"Margulis","year":"2008","journal-title":"World J Urol"},{"key":"key20180107222721_b10-or-31-02-0771","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res"},{"key":"key20180107222721_b11-or-31-02-0771","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.013243","article-title":"Interleukin enhancer-binding factor 3\/NF110 is a target of YM155, a suppressant of survivin","volume":"11","author":"Nakamura","year":"2012","journal-title":"Mol Cell Proteomics"},{"key":"key20180107222721_b12-or-31-02-0771","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.canlet.2010.12.007","article-title":"Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells","volume":"302","author":"Wang","year":"2011","journal-title":"Cancer Lett"},{"key":"key20180107222721_b13-or-31-02-0771","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/CAD.0b013e328344ac68","article-title":"YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model","volume":"22","author":"Nakahara","year":"2011","journal-title":"Anticancer Drugs"},{"key":"key20180107222721_b14-or-31-02-0771","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1158\/1078-0432.CCR-08-0468","article-title":"Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines","volume":"14","author":"Iwasa","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20180107222721_b15-or-31-02-0771","first-page":"1797","article-title":"Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan","volume":"16","author":"Tzeng","year":"1996","journal-title":"Anticancer Res"},{"key":"key20180107222721_b16-or-31-02-0771","first-page":"1469","article-title":"BDNF mediated TrkB activation is a survival signal for transitional cell carcinoma cells","volume":"36","author":"Huang","year":"2010","journal-title":"Int J Oncol"},{"key":"key20180107222721_b17-or-31-02-0771","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.tcmj.2013.05.002","article-title":"Brain-derived neurotrophic factor plus vascular endothelial growth factor additively promotes early growth of the transitional cell carcinoma cell line BFTC905 in vitro and in vivo","volume":"25","author":"Lai","year":"2013","journal-title":"Tzu Chi Med J"},{"key":"key20180107222721_b18-or-31-02-0771","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1158\/1535-7163.MCT-07-0281","article-title":"Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT","volume":"6","author":"Chao","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"key20180107222721_b19-or-31-02-0771","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pedneo.2012.04.008","article-title":"Novel survivin inhibitor YM155 elicits cytotoxicity in glioblastoma cell lines with normal or deficiency DNA-dependent protein kinase activity","volume":"53","author":"Lai","year":"2012","journal-title":"Pediatr Neonatol"},{"key":"key20180107222721_b20-or-31-02-0771","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00941899","article-title":"Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer","volume":"25","author":"Liukkonen","year":"1997","journal-title":"Urol Res"},{"key":"key20180107222721_b21-or-31-02-0771","first-page":"901","article-title":"Variable levels of bcl-2, bcl-X and bax mRNA in bladder cancer progression","volume":"5","author":"Gazzaniga","year":"1998","journal-title":"Oncol Rep"},{"key":"key20180107222721_b22-or-31-02-0771","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1016-3190(10)60067-5","article-title":"Overexpression of securin in human transitional cell carcinoma specimens","volume":"22","author":"Lai","year":"2010","journal-title":"Tzu Chi Med J"},{"key":"key20180107222721_b23-or-31-02-0771","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1357-2725(03)00213-9","article-title":"The translationally controlled tumour protein (TCTP)","volume":"36","author":"Bommer","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"key20180107222721_b24-or-31-02-0771","doi-asserted-by":"crossref","first-page":"105203","DOI":"10.1155\/2012\/105203","article-title":"TCTP in development and cancer","volume":"2012","author":"Koziol","year":"2012","journal-title":"Biochem Res Int"},{"key":"key20180107222721_b25-or-31-02-0771","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10637-009-9333-6","article-title":"A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma","volume":"29","author":"Lewis","year":"2011","journal-title":"Invest New Drugs"},{"key":"key20180107222721_b26-or-31-02-0771","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4111\/kju.2011.52.1.55","article-title":"Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells","volume":"52","author":"Yoon","year":"2011","journal-title":"Korean J Urol"},{"key":"key20180107222721_b27-or-31-02-0771","first-page":"61","article-title":"Urothelial cancer cell response to combination therapy of gemcitabine and TRAIL","volume":"39","author":"Moibi","year":"2011","journal-title":"Int J Oncol"},{"key":"key20180107222721_b28-or-31-02-0771","first-page":"1681","article-title":"The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2","volume":"32","author":"Yoon","year":"2012","journal-title":"Anticancer Res"},{"key":"key20180107222721_b29-or-31-02-0771","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1126\/science.285.5426.418","article-title":"Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis","volume":"285","author":"Zou","year":"1999","journal-title":"Science"},{"key":"key20180107222721_b30-or-31-02-0771","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cbi.2013.03.011","article-title":"Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells","volume":"203","author":"Yu","year":"2013","journal-title":"Chem Biol Interact"},{"key":"key20180107222721_b31-or-31-02-0771","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.fct.2012.01.040","article-title":"Mechanism of cisplatin resistance in human urothelial carcinoma cells","volume":"50","author":"Yu","year":"2012","journal-title":"Food Chem Toxicol"},{"key":"key20180107222721_b32-or-31-02-0771","first-page":"1265","article-title":"Overexpression of BDNF and TrkB in human bladder cancer specimens","volume":"24","author":"Lai","year":"2010","journal-title":"Oncol Rep"},{"key":"key20180107222721_b33-or-31-02-0771","first-page":"943","article-title":"TrkB antibody elicits cytotoxicity and suppresses migration\/invasion of transitional cell carcinoma cells","volume":"37","author":"Huang","year":"2010","journal-title":"Int J Oncol"},{"key":"key20180107222721_b34-or-31-02-0771","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1535-7163.MCT-12-0167","article-title":"YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels","volume":"11","author":"Kumar","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"key20180107222721_b35-or-31-02-0771","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/sj.bjc.6605713","article-title":"Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs","volume":"103","author":"Iwasa","year":"2010","journal-title":"Br J Cancer"},{"key":"key20180107222721_b36-or-31-02-0771","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1124\/jpet.112.195925","article-title":"Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab","volume":"343","author":"Kita","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"key20180107222721_b37-or-31-02-0771","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.leukres.2013.05.010","article-title":"Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma","volume":"37","author":"Kaneko","year":"2013","journal-title":"Leuk Res"},{"key":"key20180107222721_b38-or-31-02-0771","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-10-3410","article-title":"Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models","volume":"17","author":"Yamanaka","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107222721_b39-or-31-02-0771","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood-2012-05-427773","article-title":"Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia","volume":"121","author":"Chen","year":"2013","journal-title":"Blood"},{"key":"key20180107222721_b40-or-31-02-0771","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/25141","article-title":"Control of apoptosis and mitotic spindle checkpoint by survivin","volume":"396","author":"Li","year":"1998","journal-title":"Nature"},{"key":"key20180107222721_b41-or-31-02-0771","first-page":"1065","article-title":"siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth","volume":"25","author":"Ning","year":"2004","journal-title":"Int J Oncol"},{"key":"key20180107222721_b42-or-31-02-0771","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-11-2592","article-title":"Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors","volume":"18","author":"Ghadimi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20180107222721_b43-or-31-02-0771","first-page":"179","article-title":"Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter","volume":"3","author":"Cheng","year":"2012","journal-title":"Int J Biochem Mol Biol"},{"key":"key20180107222721_b44-or-31-02-0771","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science"},{"key":"key20180107222721_b45-or-31-02-0771","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0092-8674(94)90543-6","article-title":"Cyclins and cancer. II: cyclin D and CDK inhibitors come of age","volume":"79","author":"Hunter","year":"1994","journal-title":"Cell"},{"key":"key20180107222721_b46-or-31-02-0771","doi-asserted-by":"crossref","first-page":"133ra56","DOI":"10.1126\/scitranslmed.3003713","article-title":"Survivin is a therapeutic target in Merkel cell carcinoma","volume":"4","author":"Arora","year":"2012","journal-title":"Sci Transl Med"},{"key":"key20180107222721_b47-or-31-02-0771","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown","volume":"182","author":"Scholzen","year":"2000","journal-title":"J Cell Physiol"},{"key":"key20180107222721_b48-or-31-02-0771","first-page":"867","article-title":"Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67","volume":"138","author":"Gerdes","year":"1991","journal-title":"Am J Pathol"},{"key":"key20180107222721_b49-or-31-02-0771","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3727\/096504012X13340632812550","article-title":"Gene silence-induced downregulation of survivin inhibits bladder cancer cells","volume":"19","author":"Gou","year":"2011","journal-title":"Oncol Res"},{"key":"key20180107222721_b50-or-31-02-0771","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/j.1464-410X.2010.09259.x","article-title":"Cytotoxicity and apoptosis by survivin small interfering RNA in bladder cancer cells","volume":"106","author":"Ku","year":"2010","journal-title":"BJU Int"},{"key":"key20180107222721_b51-or-31-02-0771","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/1471-2407-12-619","article-title":"Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells","volume":"12","author":"Tao","year":"2012","journal-title":"BMC Cancer"},{"key":"key20180107222721_b52-or-31-02-0771","doi-asserted-by":"crossref","first-page":"33533","DOI":"10.1074\/jbc.273.50.33533","article-title":"Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant","volume":"273","author":"Oliver","year":"1998","journal-title":"J Biol Chem"},{"key":"key20180107222721_b53-or-31-02-0771","first-page":"569","article-title":"YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer","volume":"39","author":"Yamanaka","year":"2011","journal-title":"Int J Oncol"},{"key":"key20180107222721_b54-or-31-02-0771","first-page":"305","article-title":"\u03b3-H2AX - a novel biomarker for DNA double-strand breaks","volume":"22","author":"Kuo","year":"2008","journal-title":"In Vivo"},{"key":"key20180107222721_b55-or-31-02-0771","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2005.10.003","article-title":"\u03b3-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair","volume":"20","author":"Chowdhury","year":"2005","journal-title":"Mol Cell"},{"key":"key20180107222721_b56-or-31-02-0771","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.prp.2009.06.018","article-title":"siRNA targeting survivin inhibits growth and induces apoptosis in human renal clear cell carcinoma 786-O cells","volume":"205","author":"Zhang","year":"2009","journal-title":"Pathol Res Pract"},{"key":"key20180107222721_b57-or-31-02-0771","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1677\/ERC-08-0012","article-title":"Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update","volume":"15","author":"Salehi","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"key20180107222721_b58-or-31-02-0771","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1124\/mol.105.015503","article-title":"The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells","volume":"69","author":"Chao","year":"2006","journal-title":"Mol Pharmacol"},{"key":"key20180107222721_b59-or-31-02-0771","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/jemt.22103","article-title":"Expression and localization of translationally controlled tumor protein in rat urinary organs","volume":"75","author":"Sheverdin","year":"2012","journal-title":"Microsc Res Tech"},{"key":"key20180107222721_b60-or-31-02-0771","doi-asserted-by":"crossref","first-page":"969","DOI":"10.4161\/auto.6822","article-title":"CCL2, survivin and autophagy: new links with implications in human cancer","volume":"4","author":"Roca","year":"2008","journal-title":"Autophagy"},{"key":"key20180107222721_b61-or-31-02-0771","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3264","article-title":"Killing a cancer: what are the alternatives?","volume":"12","author":"Kreuzaler","year":"2012","journal-title":"Nat Rev Cancer"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2013.2882\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:29:26Z","timestamp":1597105766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2013.2882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,28]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,11,28]]},"published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.3892\/or.2013.2882"],"URL":"https:\/\/doi.org\/10.3892\/or.2013.2882","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,28]]}}}